Arcutis Biotherapeutics, Inc. - Common Stock (ARQT)

Historical Holders from Q1 2020 to Q3 2025

Symbol
ARQT on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
120M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
126M
Holdings value
$2.37B
% of all portfolios
0.004%
Grand Portfolio weight change
0%
Number of holders
233
Number of buys
116
Number of sells
-104
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JENNISON ASSOCIATES LLC 10.2% +6% $231M $16.8M 12.3M +7.86% Jennison Associates LLC 30 Sep 2025
PRUDENTIAL FINANCIAL INC 10.1% $176M 12M PRUDENTIAL FINANCIAL INC 31 Mar 2025
Frazier Life Sciences VIII, L.P. 7.5% $130M 8.94M Patrick J. Heron 18 Aug 2025
Polar Capital Holdings Plc 4.2% -24.2% $75.1M -$25.5M 5.01M -25.3% Polar Capital Holdings Plc 30 Jun 2025

Institutional Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 126M $2.37B -$12.7M $18.85 233
2025 Q2 127M $1.78B +$21.6M $14.02 228
2025 Q1 125M $1.95B -$63.3M $15.64 239
2024 Q4 129M $1.79B +$13.8M $13.93 206
2024 Q3 129M $1.2B +$15.9M $9.30 187
2024 Q2 127M $1.18B +$9.24M $9.30 184
2024 Q1 125M $1.24B +$285M $9.91 166
2023 Q4 101M $327M +$79.2M $3.23 130
2023 Q3 67.2M $357M -$26.6M $5.31 131
2023 Q2 71.8M $684M -$5.75M $9.53 135
2023 Q1 71.6M $788M +$44.3M $11.00 141
2022 Q4 65.6M $971M +$87.4M $14.80 138
2022 Q3 59.4M $1.13B +$195M $19.11 138
2022 Q2 49.1M $1.05B +$17.6M $21.31 112
2022 Q1 48.3M $930M -$136M $19.26 106
2021 Q4 46.3M $961M -$1.85M $20.74 89
2021 Q3 45.7M $1.09B +$4.82M $23.89 103
2021 Q2 45.5M $1.24B -$38M $27.29 100
2021 Q1 46.8M $1.35B +$171M $28.93 93
2020 Q4 41M $1.15B +$139M $28.13 78
2020 Q3 34.8M $1.02B +$28.9M $29.30 62
2020 Q2 33.8M $1.02B +$33.1M $30.24 55
2020 Q1 32.7M $974M +$973M $29.80 49